文献速递支持与姑息治疗

神经内分泌肿瘤诊断时类癌综合征的发生频率:一项基于人群的研究

Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
PubMed 文献 · Lancet Oncol · 2017-02-24

该研究利用美国SEER-Medicare数据库,纳入2000年4月1日至2011年12月31日期间诊断的9512例≥65岁神经内分泌肿瘤患者,评估诊断前后3个月内类癌综合征的发生率及相关临床因素。结果显示1786例(19%)存在类癌综合征,其与肿瘤分级、分期和原发部位显著相关,且类癌综合征患者总生存期较短(中位5年 vs 5.6年;HR 1.102)。

要点

  • 神经内分泌肿瘤患者中19%在诊断时存在类癌综合征。
  • 类癌综合征与肿瘤分级、分期和原发部位显著相关。
  • 类癌综合征患者总生存期较短(中位5年 vs 5.6年;HR 1.102)。

核心结论

  • 基于人群的分析显示,类癌综合征与肿瘤分级、分期和原发部位显著相关,且相比无类癌综合征患者生存期更短。
  • 作者认为,增进对神经内分泌肿瘤患者症状异质性的了解可能有助于实现比目前更个体化的评估和管理,并为未来研究类癌综合征控制对患者生存的影响提供可能。

研究设计与样本

  • 基于美国监测、流行病学和最终结果(SEER)-Medicare数据库的人群分析,纳入≥65岁神经内分泌肿瘤患者,排除胰腺肿瘤、小细胞或大细胞肺癌以及数据不完整者。
  • 共纳入9512例在2000年4月1日至2011年12月31日期间诊断的合格患者,评估诊断前后3个月内至少两次保险索赔记录中有潮红、腹泻或类癌综合征的情况。
  • 采用χ2检验比较有无类癌综合征患者的人口学和临床特征,采用Cochran-Armitage趋势检验分析类癌综合征发生率趋势,采用Cox回归评估类癌综合征与生存的关系。

主要发现

  • 9512例合格患者中,1786例(19%)有类癌综合征。
  • 有类癌综合征的患者数从2000年的50例(465例中占11%)增至2011年的160例(854例中占19%)(p<0.0001)。
  • 有无类癌综合征患者在诊断年龄(p=0.65)、地理区域(p=0.054)或城乡状态(p=0.53)方面无显著差异;有类癌综合征者女性多于男性(p=0.0003);种族(p<0.0001)、肿瘤分级、分期和原发肿瘤部位(均p<0.0001)与类癌综合征报告发生率显著相关。
  • 有类癌综合征患者总生存期较短(中位5年[95%CI 4.5-5.4]) vs 无类癌综合征患者(5.6年[5.4-5.9]);HR 1.102(1.016-1.194);p=0.019。
  • 有类癌综合征患者更常使用奥曲肽(p<0.0001)和化疗(p=0.003),而无类癌综合征患者更常接受手术(p=0.009);放疗使用与诊断时类癌综合征存在无显著关联(p=0.07)。

关键数值与推荐

  • 类癌综合征定义:诊断前后3个月内至少两次保险索赔记录中有潮红、腹泻或类癌综合征。
  • 有类癌综合征患者中位总生存期5年(95%CI 4.5-5.4),无类癌综合征患者5.6年(95%CI 5.4-5.9);HR 1.102(95%CI 1.016-1.194);p=0.019。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndrome frequency in the NET population has never been rigorously assessed, nor has its relationship to presenting clinicopathological characteristics. This analysis assessed the proportion of patients with NETs and carcinoid syndrome in the USA and associated clinical factors. METHODS: We identified patients (≥65 years of age) from the Surveillance, Epidemiology, and End Results-Medicare database, excluding those with pancreatic tumours or small-cell or large-cell lung cancer, as well as those without complete data. We assessed the incidence of patients with at least two insurance claims of flushing, diarrhoea, or carcinoid syndrome during the 3 months before and after NET diagnosis. We compared demographic and clinical characteristics between patients with and without carcinoid syndrome using χ2 tests. We used the Cochran-Armitage trend test to identify trends in carcinoid syndrome incidence and Cox regression to assess the relationship between carcinoid syndrome and survival. FINDINGS: Between April 1, 2000, and Dec 31, 2011, 9512 eligible patients were diagnosed with NETs, of whom 1786 (19%) had carcinoid syndrome. The number of patients with NETs and carcinoid syndrome increased from 50 (11%) of 465 patients in 2000 to 160 (19%) of 854 in 2011 (p<0·0001). The proportion of patients with carcinoid syndrome compared with those without did not differ significantly with respect to age at diagnosis (p=0·65), geographical region (p=0·054), or urban versus rural status (p=0·53). Patients with carcinoid syndrome were more frequently female than male (p=0·0003). Race was associated with a significant difference in the reported incidence of carcinoid syndrome (p<0·0001), as was tumour grade, stage, and primary tumour site (all p<0·0001). Patients with carcinoid syndrome had a shorter overall survival (median 5 years [95% CI 4·5-5·4]) than did those without carcinoid syndrome (5·6 years [5·4-5·9]; hazard ratio 1·102 [1·016-1·194]; p=0·019). Use of octreotide (p<0·0001) and chemotherapy (p=0·003) were more common in patients with carcinoid syndrome than in those without it, whereas surgery was used more frequently in patients without carcinoid syndrome (p=0·009); use of radiotherapy was not significantly associated with the presence of carcinoid syndrome at diagnosis (p=0·07). INTERPRETATION: This population-based analysis reveals that carcinoid syndrome is significantly associated with tumour grade, stage, and primary tumour site, and leads to shorter survival compared with those patients without carcinoid syndrome. An improved understanding of the heterogeneity of presenting symptoms among patients with NETs might permit more tailored assessment and management than at present and enable future research into the effect of carcinoid syndrome control on patient survival. FUNDING: Ipsen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017. PMID: 28238592. doi:10.1016/S1470-2045(17)30110-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。